TetraLogic Pharmaceuticals' $32m series C round sees repeat investment from Amgen Ventures.
Amgen Ventures, the $100m corporate venturing division of biotech company Amgen, has backed TetraLogic Pharmaceuticals’ $32m series C round.
Amgen had originally invested in TetraLogic, a US-based developer of drugs to treat cancer, at its $36m series B round in mid-2006, two years after the corporate venturing division was launched.
Venture capital firm Clarus Ventures led the C round, alongside peers Hatteras Venture Partners, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.
However, some of…
